AR and prostate cancer: In prostate cancer, glucocorticoid-induced activation of mutated AR has been demonstrated, which could be overcome by increased abiraterone exposure or combining abiraterone with enzalutamide.28 Preclinical studies have shown that abiraterone directly activates the ER leading to breast cancer cell proliferation.